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ed.2012.Abstract ‘Blue toe syndrome’ presents as a cyanotic toe caused by ﬁbrino-platelet micro-emboli
occlusion of the small digital arteries, with palpable pedal pulses originating from a proximal ath-
eromatous source (cardiac, aortic, femoral or popliteal aneurysm). We report a case in a 43-year-old
woman with a history of hypertension and diabetes. She was taking warfarin for extensive right
deep-vein thrombosis 6 months before her current admission. She presented with sudden onset of
severe pain, parasthaesia and bluish discolouration of the right big, second and third toes, in spite
of palpable distal pulses. Computerized tomography angiography revealed an atheromatous plaque
causing 70% stenosis of the infra-renal aorta. We therefore performed aortotomy, thrombectomy
and endartectomy. Blue toe syndrome is of clinical importance in etiology, diagnosis and treatment.
Our case had blue toe syndrome despite anticoagulant therapy.
ª 2012 Taibah University. Production and hosting by Elsevier Ltd. All rights reserved.Introduction
Blue toe syndrome was ﬁrst described by Karmody in 1976 as
acute digital cyanosis secondary to micro-embolism from a
proximal atheromatous source, despite palpable or audible
Doppler signals.1 Blue toe syndrome can occur spontaneously2
or, rarely, following anticoagulant therapy.3–6 Patients with a
recent history of an invasive vascular procedure or anticoagu-ssistant Professor in General
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07.004lant therapy are most likely to have cholesterol embolism.7,8
Establishing the source of micro-emboli is vital; therefore,
diagnosis is based ﬁrst on duplex ultrasound of the arteries
of the involved limb and echocardiography to exclude a car-
diac source. Chest and abdominal computerized tomography
and angiography are used to exclude an aortic or iliac source
of emboli. Surgery should be focused on removal of the em-
bolic source from the proximal circulation, by endartectomy,
stent grafting or a bypass procedure.9 We present a case of
blue toe syndrome with an unusual presentation, the etiology
of which was either micro-emboli or warfarin therapy.
Case report
A 43-year-old woman with history of hypertension and diabe-
tes mellitus developed extensive right femoro-popliteal deep
venous thrombosis 6 months after trauma. She had beenLtd. All rights reserved.
Figure 1: Sharply demarcated bluish discoloration of right ﬁrst,
second and third toes.
Figure 2: Reformatted sagital image delineates infra-renal aortic
atheromatous plaque causing 70% lumen encroachment.
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history of hyperlipidaemia, no previous arterial catheterization
or claudication and no family history of hypercoagulation. She
presented to the casuality department with bluish discolour-
ation of the right big, second and third toes, which were tender
to the touch, sharply demarcated, with severe pain and parast-
haesia (Figure 1). Her vital signs were stable. Physical exami-
nation revealed dusky bluish right big, second and third toes
with moderate to severe tenderness, coldness and delayed cap-
illary reﬁll. The bilateral femoral, popliteal, dorsalis pedis and
posterior tibial arteries were palpable, with no features of con-
nective tissue or Bahce’t disease. The ankle–brachial index was
normal.1
Blue toe syndrome was suspected because the peripheral
pulses were intact. The initial investigations included electro-
cardiography, which showed normal sinus rhythm, a normal
chest X-ray, which showed no cardiomegaly or congested lung,
haematological investigations such as for factor von Leiden,
proteins C and S and antiphospholipid antibody to exclude
hypercoagulation. The coagulation proﬁle was: prothrombin
time, 19.2 s; partial thromboplastin time, 28.3 s; international
normalized ratio, 1.68. Kidney function tests, lipid proﬁle, ﬁ-
brin degradation products and vasculitis screening (nuclear
antibody, DNA and extractable nuclear antigen) were normal.
Echocardiography was performed to exclude emboli. The ejec-
tion fraction of the heart was 70%, with normal left ventricle
size, trace mitral regurgitation and no pericardial effusion; left
ventricular systolic function was normal, and there was no
blood clot in the heart chambers. Intravenous heparinization
was started. Abdominal ultrasound showed a non-ulcerated,
infra-renal, 3-cm aortic atheromatous plaque causing 70% ste-
nosis in the lumen, as conﬁrmed by duplex mode. An abdom-
inal computer tomography scan with contrast and reformatted
sagital images of the abdominal aorta conﬁrmed the ultra-
sound result (Figure 2).
Surgery is the preferred treatment approach, with good re-
sults,9 and further embolization during anticoagulant therapy
should be treated with immediate surgical intervention.10 The
infra-renal aorta was approached transperitoneally by aortot-
omy. A non-ulcerated, 3-cm, yellowish atheromatic plaque was
attached to the intima, without calciﬁcation or aneurysmal
dilatation. Thrombectomy and endartectomy were performed.
Careful manipulation of the artery and clamping were adopted
to avoid plaque disruption. Histopathological examination re-
vealed a 3-cm, yellowish atheromatic plaque with a smoothsurface. Microscopically, there were many cholesterol crystals
with lipid-laden macrophages and ﬁbrous material.
The post-operative period was uneventful, with the patient
on warfarin and aspirin. Superﬁcial ischaemic changes of the
involved toes resolved within 1 month of her admission. The
patient was asymptomatic during 1 year of follow-up.
Discussion
Blue toe syndrome is the spontaneous onset of a painful bluish
discolouration of the toes caused by ﬁbrino-platelet micro-em-
boli from the abdominal aorto-iliac-femoral arterial system,
which travels down the arterial tree into the small digital ves-
sels of the foot, where it becomes lodged. The condition can
occur insidiously or may be the result of abdominal surgery
or an invasive vascular procedure (2%)7,8,11,12 that scratches
the luminal surface of the vessels, or rarely following anticoag-
ulation.3–6 Acute digital ischaemia caused by the coumarin
anticoagulant warfarin was ﬁrst described by Feder and Auer-
bach.13 It has been suggested4 that use of anticoagulants pre-
vents stabilization of the ulcerated plaque surface by clotting
and leads to gradual loss of the protective ﬁbrin layer overlying
the plaque,14 which permits cholesterol-containing debris to be
shed into the circulation. Lodgement of cholesterol clefts in
small arteries results in an inﬂammatory reaction involving
macrophage and giant cell inﬁltration. This inﬂammatory reac-
tion leads to an endothelial reaction causing intimal prolifera-
tion, intravascular ﬁbrosis of the affected vessels and
narrowing or obliteration of the lumen, which may cause tissue
ischaemia. Acute focal digital ischaemia may result from
embolism, thrombosis, mechanical obstruction or inﬂamma-
tion or from a combination of these mechanisms.15 Vasospasm
may also contribute, because endothelial cell damage from any
Etiology of ‘blue toe’ syndrome: Emboli versuswarfarin therapy 43cause impairs generation of endothelium-derived relaxation
factor and prostacyclin.15
Some reports indicate that blue toe syndrome is induced by
long-term anticoagulant therapy with warfarin, acenocouma-
rol or phenindione.5,6,16 Anticoagulant-associated cholesterol
embolization has been reported to develop 1 week to 3 years
after initiation of antiocoagulants.5,17,18 Rauh and Spengel re-
ported that cholesterol emboli may also occur in patients trea-
ted with low-dose oral anticoagulation for 2 months, with no
previous arterial catheterization.3 In patients with no obvious
embolic source, systemic abnormalities should be considered,
including circulating agglutinins, vasculitis, acrocyanosis, sys-
temic lupus erythematosus, polycythemia vera and subacute
bacterial endocarditis, as well as certain drugs such as warfarin
and prednisilone.19
The segment most commonly responsible for symptomatic
embolization is the aorta-iliac segment.20 Keen et al. noted
that 85% of emboli arose from aorto-iliac occlusive or anerys-
mal disease.20 Untreated blue toe syndrome frequently recurs
and could result in loss of a limb and death.10 Our patient
had extensive aortic atheroma that might have been due to
hypertension, atherosclerosis and diabetes mellitus. Hyperco-
agulability in diabetes mellitus can result from abnormal plate-
let function, increased blood viscosity or decreased red blood
cell deformability or from disturbances of the coagulation
and ﬁbrinolytic systems.21 Moreover, both thromboembolism
and atheroembolism can occur either spontaneously or after
an iatrogenic procedure in the aorta.12 Patients with bilateral
blue toe syndrome usually have an embologenic lesion proxi-
mal to an aortic bifurcation, while unilateral lesions are usually
associated with an atherosclerotic plaque or aneurysm distal to
the aortic bifurcation.22 Our patient had unilateral blue toe
syndromeeven though the plaque lesion was located proximal
to the aortic bifurcation.
Establishing the source of an embolism is vital. Noninva-
sive vascular assessment including ultrasound imaging to
determine the presence of an aneurysm, should be performed
in all patients.15 Computerized tomography angiography is
the preferred imaging modality for diagnosis, while angiogra-
phy is reserved for cases in which noninvasive evaluation is
not informative.23 A renal function test is often performed in
patients with bilateral lesions because deterioration in the
suprarenal aorta due to atheroemboli can lead to renal shut-
down. The standard treatment for lower limb microemboliza-
tion is removal of the embolic source.22 In our case, we used
immediate surgery as the standard treatment approach, with
good results. Further embolization during anticoagulant ther-
apy should be treated by immediate surgical intervention,10
especially for plaques located in the infra-renal aorta. Endar-
tectomy with or without patch angioplasty has been estab-
lished in the literature and should be considered the
treatment of choice when limb-threatening ischaemia is pres-
ent.10 Several authors have found antiplatelet24 and anticoag-
ulant treatment to be ineffective3 and suggested that it might
even predispose to further embolization.1 There is some evi-
dence that warfarin and heparin might actually promote fur-
ther embolization.5
Morris-Jones et al.24 used the antiplatelet drugs acetylsali-
cylic acid and dipyridamole to treat patients with blue toe syn-
drome. Treatment with aspirin or warfarin has resulted in an
overall recurrence rate of 75%.20 Therefore, anticoagulants
are generally less effective than surgical intervention.23 If a pa-tient develops the syndrome, long-term anticoagulation should
be withdrawn, if possible.16 Interestingly, it has been reported
that a patient may be become asymptomatic even if oral anti-
coagulation is continued5 or given at a lower dose
symptomatic.25
Angioplasty with stenting is effective in treating blue toe
syndrome.23 Renshaw and colleagues used percutaneous angi-
oplasty with stenting for eight patients with unilateral blue toe
syndrome and 12 haemodynamically signiﬁcant lesions: four in
the superﬁcial femoral artery, six in the common iliac and two
in the external iliac. They concluded on the basis of intermedi-
ate results that angioplasty and stenting are a reasonable alter-
native to standard operative approaches.23 Treatment with
anticoagulants and delayed angioplasty of the upstream lesion,
including in the iliac, femoral and popliteal arteries, may be an
effective alternative to surgery,10 but endovascular stenting for
treatment of aortic and arterial embolism has largely been lim-
ited to abdominal aortic and infrainguinal forms of the dis-
ease.26 Case reports have suggested a beneﬁcial role of
statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors) in stabilizing the cholesterol-rich atherosclerotic
plaque. Statins have not only a cholesterol-lowering effect
but also anti-inﬂammatory and immunomodulatory proper-
ties, which may play a role in plaque stabilization.27
There are limited data on the long-term outcome of medi-
cal, surgical or combined management of blue toe syndrome.Conclusion
A careful history and physical examination will often suggest
the cause of blue toe syndrome. For patients on anticoagulant
therapy (warfarin) who complain of toe symptoms, blue toe
syndrome should be considered. The distinctions between uni-
lateral and bilateral blue toe syndrome and between the pres-
ence or absence of associated systemic or cutaneous ﬁndings
are useful.
Surgery should focus on removal of the embolic source
from the proximal circulation. We suggest that further embo-
lization during anticoagulant or antiplatelet therapy be treated
by immediate surgical intervention. More cases and clinical tri-
als are needed to determine the optimal treatment and to cat-
egorize which patients require surgical intervention and which
can be managed safely by medical therapy or stenting.Conﬂict of interest statement
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